Physician profile
David T Devries
NPI 1467561589
$17,247.71
in general payments reported to CMS, 2019-2025
32 companies · $3,362 in 2025
The $3,362 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,021 · 2020: $1,150 · 2021: $1,185 · 2022: $3,283 · 2023: $3,154 · 2024: $3,092 · 2025: $3,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,292 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,291.61 |
| Education | $317.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,491.28 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,408.95 | 2019-2025 | |
| Janssen Biotech, INC. | $1,349.95 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $1,251.93 | 2019-2025 | |
| Leo Pharma INC. | $1,190.32 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $1,187.86 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $1,175.33 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $1,041.11 | 2022-2025 | Sotyktu |
| Ucb, INC. | $674.46 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $657.47 | 2019-2025 | Ilumya |
| Pfizer INC. | $632.12 | 2019-2025 | |
| Incyte Corporation | $579.75 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $467.48 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Arcutis Biotherapeutics, INC. | $396.18 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $308.04 | 2019-2025 | Nemluvio, Aklief |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $228.33 | 2019-2025 | Cabtreo, Jublia |
| Celgene Corporation | $207.76 | 2019 | |
| Organon LLC | $149.54 | 2024-2025 | Vtama |
| Almirall LLC | $115.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.37 | 2022-2024 | Spevigo |
| Dermira, INC. | $108.03 | 2019-2021 | |
| Epi Health, LLC | $102.73 | 2020-2022 | |
| Biofrontera INC. | $89.32 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Mayne Pharma Commercial LLC | $64.10 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $56.42 | 2019 | |
| Dermavant Sciences, INC. | $55.48 | 2022-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $51.45 | 2020-2021 | |
| Mission Pharmacal Company | $30.91 | 2020-2022 | |
| Journey Medical Corporation | $20.64 | 2022 | |
| Dusa Pharmaceuticals, INC. | $17.31 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.61 | 2024 | Ycanth |
| Medtronic USA, INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Devries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.